Life ScienceCompany
Where is Syntimmune headquartered?
Syntimmune is headquartered in Boston, Massachusetts.
What sector is Syntimmune in?
Syntimmune is a life science company.
When was Syntimmune founded?
Syntimmune was founded in 2013.
Syntimmune is headquartered in Boston, Massachusetts.
Syntimmune is a life science company.
Syntimmune was founded in 2013.
116 Huntington Ave, Suite 301,
Boston, Massachusetts
02116
United States,
(617) 206-4220
www.syntimmune.com
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. Drawing on the pioneering research of its scientific founders, the company is advancing novel therapies based on its deep expertise in the biology of the neonatal Fc receptor (FcRn) and its complex role in the pathogenesis of IgG-mediated autoimmune diseases. Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody that specifically blocks FcRn-IgG interactions and is being studied in multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune diseases. Syntimmune is headquartered in Boston, Mass. and was founded in 2013.
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.